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ABSTRACT

THE CHEMICAL ANALYSIS AND BIOLOGICAL ACTIVITIES
OF THE SECONDARY METABOLITES
FROM DALEA MOLLIS AND
DALEA ALBIFLORA

by

Nicholas Peter Hansen

June 2019

Multidrug resistance has increased since the introduction of drugs used to prevent growth
and kill microorganisms in a host. This has caused a worldwide search to discover new drugs
effective against microorganisms. Mechanisms of drug resistance include, but are not limited to,
the production of biofilms and efflux pumps. Efflux pumps prevent antimicrobial drugs from
reaching their biological target, so the coordinated use of efflux pump inhibitors and
antimicrobial drugs has been identified as a potential treatment for multidrug-resistant
microorganisms. The secondary metabolites of Dalea mollis and Dalea albiflora were tested
against multidrug-resistant (MDR) and engineered strains of the fungi Candida glabrata and
Saccharomyces cerevisiae. Two known pterocarpans, two known flavanones, and an
isoflavonoid were isolated and identified from D. mollis. Two new flavanones (albifloran A 9
and albifloran B 10), one known pterocarpan, and three known flavanones were isolated and
identified from D. albiflora. Initial results revealed that the components of D. mollis were
inactive against the fungal strains tested, but components of the roots of D. albiflora did show
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activity. VLC fractions three and four of D. albiflora inhibited the growth of the S. cerevisiae
expression host and S. cerevisiae overexpressing Snq2 with minimal inhibitory concentrations
(MIC) of 42 μg/mL and 87 μg/mL, respectively. VLC fraction four inhibited the growth of C.
glabrata overexpressing Snq2 with an MIC of 167 μg/mL.
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CHAPTER I
INTRODUCTION
Background
The pursuit of natural products through organic extraction is an important scientific field.
Natural product extraction has led to multiple discoveries of commercially and medicinally
successful compounds as varied as aspirin1, penicillin2,3 and taxol.4,5 Such discoveries are proof
that natural product extraction, in conjunction with biological testing, is a field that should
continue to be explored by chemists.
The structures that natural products chemists are interested in are termed secondary
metabolites. The difference between primary and secondary metabolites is that primary
metabolites are required for normal biological functions, structural components, genes, proteins
etc. Secondary metabolites do not apparently serve an essential function of these types. Why are
they produced, and why are there so many different types of secondary metabolites? The
structural possibilities of secondary metabolites produced by plants, sponges and other marine
organisms, bacteria, and fungi are infinite. There are several lines of thought for why the
observed diversity of such compounds is so vast. One of the thoughts is the “Screening
Hypothesis” presented by Richard D. Firn and Clive G. Jones.6 In this model, secondary
metabolites are intended to enhance the survival of the species.6 This approach assumes that
individual species are/were in a ‘chemical arms race.’6 The chemical arms race model is a
shotgun approach. If the plant, for this example, produces one hundred different compounds and
one of the compounds greatly improves the plant’s chances of survival then it was a success.
There is also a growing body of evidence to suggest that additive and synergistic effects of
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multiple compounds represent a viable chemical defense system in the absence of a single,
potent inhibitor. If there is a fungus living in the ground that survives parasitically on the roots of
a plant, the plant may evolve mechanisms to produce secondary metabolites that are effective in
preventing this parasitism by killing the fungus or inhibiting the growth of more fungus. These
compounds, that improve the fitness of their respective producer, can be isolated by chemists and
may be used for their medicinal effects. Another, less-credited, thought on why secondary
metabolites are formed is that the compounds produced are accidents and side-products of
normal metabolism.6 This approach does not consistently explain the observed advantages
gained as a result of the production of these metabolites. Organisms use energy and resources for
the production of these secondary metabolites. Because of this lack of a strong argument, the
Screening Hypothesis is the more commonly cited and accepted approach. In this thesis, the
flavonoid secondary metabolites will be examined along with their potential medicinal effects.
Flavonoid secondary metabolites are defined by a parent ring structure of C6-C3-C67,
Figure 1. The first ring is a six-carbon aromatic ring fused to a non-aromatic ring containing and
additional three carbons and an ether to form a six-membered hetero-ring. The final ring is a
phenyl group. The formal name for this core structure is 2-phenylchroman.
O
O

Figure 1: From right to left, the flavonoid parent structure (flavan) and the isoflavonoid structure
(isoflavan).7
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The flavonoid core-structure is a three-ring structure shown in Figure 2. Carbon number 2 of
flavan is a chirality center when it is sp3 hybridized. Flavonoids isolated from natural sources are
highly functionalized, allowing for an almost infinite variety of structures.
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Figure 2: The carbon atom assignments of flavan structure.
Flavonoids are biosynthetically derived from L-phenylalanine8 and 4-hydroxycinnamoylCoA.9 The biosynthetic pathway is shown in Scheme 1. The precursor molecule, 4hydroxycinnamoyl-CoA, interacts with enzymes that dictate the structures of the resulting
flavonoids. Scheme 1 shows 4-hydroxycinnamoyl-CoA interacting with three malonyl-CoA
molecules to yield intermediate 1.9 Intermediate 1 will then interact with the enzyme chalcone
synthase and form the naringenin-chalcone molecule.9 Then a Michael-type addition of the OH
group aided by chalcone isomerase will result in a ring closing to yield the compound
naringenin, a flavanone.9
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Scheme 1: The biosynthetic pathway for a flavanone originating from 4-hydroxycinnamoylCoA.9
Scheme 2 shows intermediate 1 interacting with NADPH reductase prior to chalcone synthase.
This results in isoliquiritigenin, instead of naringenin-chalcone. Isoliquiritigenin then goes
through the same ring closing mechanism resulting in liquiritgenin.9
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Scheme 2: The biosynthetic pathway for flavanones from 4-hydroxycinnamoyl-CoA when
interacting with a NADPH reductase enzyme.9
The flavonoid can be isomerized to an isoflavonoid (Figure 1). The production of
isoflavonoids is common in the Fabaceae family.9 The pathway for the biosynthesis of
isoflavonoids begins with liquiritigen, Scheme 2, which interacts with a cytochrome P-450dependent enzyme also known as 2-hydroxyisoflavone synthase (denoted as E1 in Scheme 3),
NADPH, and O2 as a cofactor.9–11 The enzyme active site has a terminal iron-oxo group. This
oxygen will deprotonate one of the hydrogens on C-3 of liquiritigenin resulting in a radical. This
will lead to a 1,2-aryl migration. The radical on C-2 will then be stabilized by the addition of a
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hydroxy group from E1. A dehydration will occur next when the molecule interacts with 2hydroxyisoflavanone dehydratase (denoted as E2 in Scheme 3).11 This step results in the product
daidzein.9,11

Scheme 3: The biosynthetic pathway for the production of the isoflavonoid daidzein.9–12
Isoflavonoids can be further modified to form another compound type called
pterocarpans. A ubiquitous example of the pterocarpan family is the compound medicarpin,
isolated in this project. A biosynthetic scheme for the synthesis of medicarpin is shown in
Scheme 4.

6

Scheme 4: The pathway for the production of medicarpin from daidzein.9–12
Prenyl groups are a common substituent of flavonoid metabolites, and likely have a role
in associated activity or bioavailability.13–17 The prenyl group is a five carbon chain with one
double bond, Figure 3.

Figure 3: The two common prenyl group types.
Prenyl groups are usually attached to flavonoids using a regioselective prenyltransferase,
dimethylallyl diphosphate (DMAPP) and 8-dimethylallyl transferase (N8DT).13,14,18 This
addition is illustrated in Scheme 5.

7

Scheme 5: Naringenin interacts with dimethylallyl diphosphate (DMAPP) and 8-dimethylallyl
transferase (N8DT).14
Dalea spp. are prolific producers of phenolic metabolites, particularly of the flavonoid
class. Flavonoids have exhibited antiinflammatory, antioxidant, antibacterial, antifungal, and
antiparasitic activities.14,16,17,19–24 Representative work on the genus Dalea may be highlighted
by an examination of metabolites of D. spinosa21, D. searlsiae17 D. formosa22 and D. ornata.23
Compounds isolated from D. spinosa were tested against multidrug-resistant (MDR)
Staphylococcus aureus.21 The novel compounds spinosan A and spinosan B (Figure 4), both
arylbenzofurans, (a flavan with a five-membered C-ring9) were effective in inhibiting efflux
pumps in MDR S. aureus. As a result, spinosan A potentiated the effects of a plant-derived
antimicrobial drug, berberine, on MDR S. aureus.

Figure 4: The structures of the benzofurans isolated from D. spinosa.21
8

Compounds of D. searlsiae showed antimicrobial and antiinsectan activities.17 The four
novel D. searlsiae compounds exhibited minimum inhibitory concentrations (MICs) ranging
from 2-8 µM against multiple bacteria including S. aureus. The novel compound malheuran
D(Figure 5), also caused a 90% growth reduction and a 37% mortality against the fall armyworm
Spodoptera frugiperda, an important crop pest. Interestingly, the malheuran derivatives have a
less-common variation of the prenyl side-chain known as a geranyl group.

Figure 5: The structures of the flavonoid derivatives isolated from D. searlsiae.17
Compounds isolated from D. formosa showed good antifungal activity against Candida
albicans and C. glabrata.22 Sedonan A exhibited direct antifungal activity against C. glabrata
with an MIC of 20 µM. A combination of the compounds sedonan A and ent-sandwicensin
(Figure 6) synergistically inhibited the growth of these same two fungi. Sedonan A incorporates
a cyclized version of the prenyl functional group to create as a dimethylpyran ring.
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Figure 6: The structures of isoflavonoid derivatives isolated from D. formosa.22
D. ornata secondary metabolites exhibited a range of ex vivo anthelmintic (antiparasitic
worm) activities against the parasitic hookworm Ancylostoma ceylanicum.23 The novel
compound (2S)-8-(3-methylbut-2-en-1-yl)-6,7’,4’-trihydroxyflavanone exhibited a 17%
mortality to A. ceylanicum after the five days of exposure. The two rotenones, (-)-deguelin and ()-tephrosin (Figure 7), exhibited strong anthelmintic activity, resulting in 100% mortality within
the five days of exposure. (-)-Tephrosin resulted in complete worm mortality after three days of
exposure at 6.0 µM, while (-)-deguelin took one more day and a higher concentration. The only
structural difference between these two compounds is the C-12a hydroxy group of (-)-tephrosin.
Rotenoids, a flavonoid sub-class, have previously exhibited antiinsectan and fish poisoning
activities.9 It has been reported that rotenoids act via inhibition of the electron transport
chain.23,25
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Figure 7: The structures of two the rotenones isolated from D. ornata.23
The continued findings of novel structures and activities in these studies of Dalea spp.
suggest that the genus is still a good source of new compounds with the potential for medicinal
value. The biodiversity of flavonoid structures is potentially infinite. In nearly each different
species of Dalea studied, our research group has encountered ever-changing variations in
structures. This biodiversity is another reason for further research into the isolation of more
secondary metabolites from unexplored Dalea spp. In terms of drugs and drug discovery, the
flavonoid core is the pharmacophore structure and further derivations of the core are referred to
as auxophoric groups.3 As an aside, the opioid pharmacophore is a well-known example of how
derivatives of a compound core can lead to varied biological action. In the opioid core structure,
the substitution of a hydrogen by an acetyl group represents the difference between morphine
and its more potent derivative heroin (Figure 8).3
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Figure 8: The structural comparison of morphine and heroin.3
Herein, is the exploration of the secondary metabolites of the species Dalea mollis and
Dalea albiflora. In the screening of additional Dalea spp. that arose from the D. ornata
anthelmintic project23, both D. mollis and D. albiflora showed no activity against the human
pathogenic hookworm A. ceylanicum. This did not stop the exploration of the secondary
metabolites of these plant materials. D. mollis was also screened against multiple bacteria and
fungi, but unfortunately, to date, has shown no biological activity. The crude extracts of the root
portions of D. albiflora showed activity against MDR-fungi and other specialized test-strains of
Candida and Saccharomyces.
Biological Significance
There has been an alarming rise of drug-resistant microorganisms.3,22,23,26,27Antimicrobial
drug resistance occurs when a once-effective dose of antibiotic(s) is no longer effective in killing
or inhibiting the growth of a microorganism.3 The reasons for this are varied, including overprescription of antibiotics, improper/incomplete cycles of antibiotics, mutations in the pathogen,
ineffective chemotherapy treatments and gene-sharing between pathogens.27 Common
mechanisms of drug resistance are the growth of biofilms28 and the production of efflux pumps.29
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Biofilms are extracellular polymers that provide a layer between the pathogen’s cell(s) and the
intended drug.28 These polymers can attach to almost any surface, biological or non-biological.
In Figure 9, the growth of multiple Candida species including the production of biofilms. The
early phase of the Candida life cycle does not include a biofilm. As the species matures, a small
layer of the biofilm is produced along with additional cells. At full maturity, the biofilm is
completely formed and able to protect the cells from external hazards.

Figure 9: The growth of biofilms of Candida species during the maturation process.28
Efflux pumps are transmembrane proteins that remove harmful molecules from the cell.29
An efflux pump inhibitor would prevent this action, even allowing weaker drugs to be effective
even against drug resistant microorganisms. Figure 10 shows a cross-section of a cell-membrane
with an ATP-binding cassette (ABC) transporter. Antibiotics often enter the cell by diffusion
through the membrane, but are quickly pumped out by the overexpression of efflux transporters.
In this case, the transporter has been deactivated by the test substance, red X in figure 10, by an
interaction at a yet-to-be-determined site of the transport protein. This allows for the
antifungal/antibiotic drug, green in Figure 10, to remain inside the cell and continue its action.
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Figure 10: Overcoming multi-drug resistance (MDR) by addition of an efflux pump (ABC
transporter) inhibitor in conjunction with an antifungal antibiotic.
The fungal species Candida albicans and Candida glabrata are the two species most
often responsible for candidiasis infection.27,30,31 C. albicans, C. glabrata, and S. cerevisiae all
share the common ancestor Yarrowia lipolytica.31 Interestingly, C. glabrata is more closely
related to S. cerevisiae than it is to the other Candida spp.31 C. glabrata is a particular harmful
fungus that can survive even after being engulfed in a phagocyte.30 This survivability makes C.
glabrata a very difficult infection to deal with. The antibiotic compound family called azoles has
long been useful for its antifungal activities.27,30–32 Unfortunately, Candida and Saccharomyces
species are prolific producers of ABC transporters.27,32 In MDR organisms, these transporters are
typically over-expressed, effectively detoxifying the cell before azole or other antibiotics have
time to work.32 In Candida, one of the more common transporters is the 1501 amino acid
Candida drug resistance 1 (Cdr1) efflux pump.27 The Cdr1 transporter has a high substrate
specificity towards fluconazole, one of the most used antifungal drugs.32 Candida have adapted
to produce more than just the Cdr1 efflux pump. Alternate/ additional efflux pumps include
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Snq2, Yor1, and Pdr1.27,32–34 Because of these efflux pumps, azoles have become less effective
against MDR fungi. Strategies to combat this MDR include the introduction of new direct-action
antifungal drugs, or the co-administration of an efflux pump inhibitor and an antifungal drug.
The research group of Dr. Marcin Kolaczkowski, Wroclaw Medical University, Poland,
has investigated the nature of MDR in multiple pathogenic fungi. Kolaczkowski et al. have
collaborated previously with our research on Dalea spp. An earlier result of this work was the
discovery of sedonan A, from D. formosa, which exhibited a 20 µM MIC against Candida
glabrata.22 The Kolaczkowski group specializes in observing the effects of lead compounds or
existing drugs against multidrug-resistant fungi. The group has cultured strains of fungi
including, but not limited to, Saccharomyces cerevisiae, Candida albicans, and Candida
glabrata, with either under- or over-expression of multiple efflux pumps including the multidrug transporters Cdr1, Pdr5, Snq2 and Yor1.32,33,35 The mode of action of metabolites against
the fungi can be determined, in part based on how lethal the metabolites are against both underand over-expressing strains of the fungi.
Chemical Theory
Isolation of compounds of interest is achieved through multiple liquid chromatographic methods.
Chromatography is a separation process in which analytes dissolved in a mobile phase travel
through an immiscible stationary phase.36 Throughout this project, open column chromatography
was the primary method of use, as opposed to instrumental separation methods like high
performance liquid chromatography (HPLC). The separation of the analytes can technically be
defined by the relationship between the concentration of an analyte in the mobile and stationary
phases, as shown in Equation 1. Where Kc is the partition coefficient, [A]s is the concentration of
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the analyte in the stationary phase (adsorbed to the silica), and [A]m is the concentration of the
analyte in the mobile phase (not adsorbed to the silica).36
𝐾" =

[&](

(1)

[&])

Being able to maximize column efficiency is a major concern for chemists attempting to
separate like compounds. While calculations were not performed to maximize column efficiency
in this research, fundamental aspects of these concepts were applied. The height and width of the
columns used were dependent on the mass, purity, and polarity of components present in the
sample being purified. The extensive use of thin layer chromatography (TLC) prior to separation
provided critical information about the sample. TLC helped determine complexity of mixtures
and the relative polarities of the components in a mixture. The increased number of theoretical
plates on TLC allowed for high selectivity and band resolution. This gave vital information for
the parameters needed for a successful purification. With the oversight of the principal
investigator for initial purification procedures, it soon became easier to independently establish
the packed-column dimensions needed for an effective separation. Multiple liquid
chromatographic methods were used, including vacuum liquid chromatography (VLC),
Sephadex LH-20 chromatography, and varieties of open-column silica gel chromatography. The
reasoning behind using multiple and variable methods is to maximize the amount of compounds
separated and recovered. VLC is a quick method that utilizes a wide range of polarities and a
large volume of solution. This allows for a large group of compounds with similar polarity to be
isolated. The next technique is Sephadex chromatography. Sephadex LH-20 is a porous size
exclusion polymer. Depending on the mobile phase, the Sephadex pore size will vary, and the gel
will either swell or contract. In our laboratory, two solvent systems are used in succession. A
mixture with a volumetric ratio of 3:1:1 hexane, toluene and methanol is used as the first system
16

and then a 100% methanol system is used. The pores contract in the 3:1:1 mixture, allowing for
larger molecules to pass by while smaller molecules get trapped within the pores. The methanol
system expands the pores allowing for those smaller molecules to elute later in the sequence.
Open-column chromatography, using 70-230 mesh grade silica gel, is used to further separate
compounds based on polarity. If multiple techniques were not used, achieving band resolution in
successive steps would be much more difficult and require more time and resources.
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CHAPTER II
METHODS
Extraction
Plants of interest, Dalea mollis and Dalea albiflora, were collected in Arizona. Dalea
mollis Benth was collected west of Phoenix, AZ by Dr. Belofsky, Figure 11. Dalea albiflora A.
Gray was collected south of Flagstaff and north of Sedona, AZ by Dr. Belofsky and this author,
Figure 11.

Figure 11: Dalea mollis on the left and Dalea albiflora on the right.
David Giblin, of the University of Washington, authenticated the taxonomic identification of the
two species. The plants were air-dried for 48-72 hours following collection. The aerial and roots
parts of the plants were separated, since prior studies in our group have shown that the chemical
composition of these are typically different.17 Both portions of the dried plants were weighed and
a smaller portion of the dried material was vacuum-sealed and frozen as a reserve of the original
plant material. The bulk of the collected plant material was blended in methanol (MeOH). The
blended material and the MeOH were vacuum filtered and the filtrate was rotary-evaporated.
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Chromatography
The dried crude extract was weighed and prepared for vacuum-liquid chromatography
(VLC) by pre-adsorption to silica gel, followed by evaporation. Elution in VLC used a non-polar
to polar solvent gradient. The elution typically proceeded with ~1 L each of solvents of the
following compositions: 100% hexane, 20% v/v ethyl-acetate (EtOAc) in hexane, 40%
EtOAc/hexane, 60% EtOAc/hexane, 80% EtOAc/hexane, 100% EtOAc, 2% v/v (MeOH) in
dichloromethane (DCM), 5% MeOH/DCM, 8% MeOH/DCM, 10% MeOH/DCM, 30%
MeOH/DCM. These column fractions were rotatory evaporated and examined by thin-layer
chromatography (TLC).
Analysis of the TLC results of the VLC fractions and the recovered weights, led to the
selection of a representative 2 g mixture, consisting of materials taken from VLC fractions, for
further purification by Sephadex LH-20 column chromatography. This column chromatography
procedure was a multi-day process beginning with isocratic elution with 3:1:1 v/v/v
hexane/toluene/MeOH and ending with a 100% MeOH wash. This typically produces close to
200 8mL fractions in test tubes. The fractions were examined by TLC and fractions of similar
composition were combined and weighed.
Sets of the resulting Sephadex column fractions were then purified through several stages
of further column chromatography, including step-gradient and continuous gradient open-column
procedures. The procedures used were dependent on the relative purity, TLC-based polarity
characteristics, and the mass of the fraction(s). Lower mass fractions were necessarily purified
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on smaller columns to avoid loss from dilution of the eluents while on the column, due to bandspreading. Larger fractions were accordingly purified on larger columns.
Characterization
Once purity was achieved, the fractions were analyzed using nuclear magnetic resonance
(NMR) spectroscopy. It should be noted that the Bruker 400 MHz NMR spectrometer typically
affords good 13C NMR signal-to-noise ratios for samples at or above ~2-4 mg, depending on the
molecular weight of the compound(s). This was kept in mind when making difficult choices to
exclude certain lower weight fractions from further purification and characterization work. NMR
samples were typically dissolved in acetone-d6. 1H NMR spectroscopic analyses provided initial
information on the purity of the fraction and the general class of compound of the molecule(s).
The proton spectrum was then compared to those of an in-house database of previously
discovered compounds. If this comparison yielded an exact match, no further NMR
spectroscopic analyses were conducted beyond 1H and 13C NMR acquisitions. If no match was
revealed, extensive NMR analyses were conducted. In addition to acquisition of the standard 13C
carbon NMR spectrum, Distortionless Enhancement of Polarization Transfer (DEPT) 135 and
DEPT 90 analyses are performed. While 13C NMR spectroscopy provides signals for all the
carbons in the molecule, DEPT 135 distinguishes methylene (CH2) signals from methyl (CH3)
and methine (CH) signals. DEPT 90 then further distinguishes methine from methyl signals.
Once 1H and 13C NMR spectroscopic data had been collected, extensive two-dimensional NMR
analyses were needed. These included heteronuclear single quantum coherence (HSQC) and
heteronuclear multiple bond correlation (HMBC) spectroscopy. HSQC shows the correlation of
two atoms that are bonded to each other. For the purpose of this research, the correlation was for
hydrogen atoms bonded to carbon atoms. HMBC reveals correlations to carbon atoms that are
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two and three bonds away from a proton. Using these methods, the structures of molecules can
be deduced. Primary characterization of the compounds was now be achieved, to be later
supported by mass spectrometry (MS) and other physico-chemical measurements like infrared
(IR) and ultraviolet (UV) spectroscopy, melting point (mp), and specific rotation by polarimetry.
In some cases, absolute configuration was determined by electronic circular dichroism (ECD),
performed with collaborators.
Biological Testing
Biological testing ideally occurs throughout the fractional process. Due to the lowthroughput limitations of some of our bioassays, testing was necessarily limited to the crude
extract, selected VLC fractions, and isolated compounds. All antifungal testing for the
metabolites of D. albiflora was performed by the collaborative group, headed by Dr. Marcin
Kolaczkowski of Wroclaw Medical University, Poland.
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CHAPTER III
RESULTS AND DISCUSSION
Dalea mollis - Experimental
Optical rotations were recorded on a PerkinElmer 341 polarimeter (Na lamp, 589 nm);
concentrations are reported as g/ 100 mL. UV spectra were recorded using an HP-Agilent 8453
photodiode array instrument. IR spectra were obtained on a Nicolet Protégé 460 spectrometer,
via KBr plates. NMR spectra were obtained on a Bruker Avance 400 MHz system with Topsin
1.3 software. TLC plates (Sigma-Aldrich; silica gel 60, F254) were eluted with mixtures of MeOH
in DCM or of EtOAc in hexanes. Spots were visualized with UV (254 nm) and scorched after
being sprayed with reagent vanillin – H2SO4 (1 g/ 100 mL w/v). All solvents were purchased
from Sigma-Aldrich.
Dalea mollis was collected at two different sites in Arizona and the TLC comparisons of
the two sites showed a similar chemical composition. The two sites were combined for the
remainder of the experiments performed. The aerial portion of D. mollis resulted in eleven VLC
fractions. VLC fractions one and two were subsequently partitioned between hexane and
aqueous MeOH (10% H2O in MeOH) to attempt to remove oils from other compounds of
potential interest. VLC fractions three, four, five, six and seven were combined into a
representative 2.02 g mixture and sent through a Sephadex LH-20 column. Sephadex fractions
were collected in 8 mL portions and like fractions combined after visualization on TLC. The
known compound (-)-euchrenone-a7 (3), 25.8 mg, was isolated from Sephadex test tube fractions
166 – 173, resulting in four distinct fractions. These four fractions were combined and passed
through a linear gradient column. The known compound (+)-4-hydroxymedicarpin (2), 6.8 mg,
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was isolated using a linear gradient and step gradient column. VLC fraction two was partitioned
using a hexane/aqueous methanol wash. Two grams of the resulting hexane layer, 7.06 g, was
passed through a Sephadex column. The known compound (-)-glabranine (4), 8.5 mg, was then
isolated after one linear gradient column.
The root portion of D. mollis resulted in eleven VLC fractions. VLC fractions three, four,
five, and six were combined into a 723.2 mg representative mixture and passed through a
Sephadex LH-20 column. The known compound (+)-medicarpin (1), 2.5 mg, was then isolated
after a linear gradient and a step-wise gradient column. The known compound (-)-4’-Omethylpreglabridin (5), 5.8 mg, was isolated after one linear gradient column and one step-wise
gradient column. The compound 2(S)-5¢-(1¢¢¢,1¢¢¢-di-methylallyl)-8-(3¢¢,3¢¢-dimethylallyl)2¢,4¢,5,7-tetrahydroxyflavanone (6), 153.7 mg, was isolated after one linear gradient column.
Dalea mollis - Results and Discussion
Crude extracts of D. mollis were tested against the human pathogenic hookworm A.
ceylanicum in the initial screening process of Dalea spp. related to the prior NIH-funded work.
The components of D. mollis showed no significant activity against A. ceylanicum. The
components of D. mollis were also tested against the yeast fungi: S. cerevisiae, C. albicans, and
C. glabrata. There was no significant biological activity against these fungi. Lastly, the
components of D. mollis were exposed to various species of pathogenic bacteria. Once again,
there was no significant biological activity. The focus of the D. mollis project was then shifted to
compound discovery. All six of the isolated compounds in D. mollis are previously known
compounds.
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Carbons and their attached protons were correlated using HSQC and multiple bond
correlations were determined by HMBC for the compounds shown in Figure 12.

Figure 12: The structures of isolated metabolites of Dalea mollis.
The 1H and 13C NMR spectra of compounds 1 and 2 revealed a pterocarpan core
structure. Comparison of spectroscopic data and TLC with authentic samples previously isolated
from the Belofsky group confirmed the identities of compounds 1 and 2.
The 1H and 13C NMR spectra of compound 3 revealed a flavanone core structure.
Comparison of spectroscopy data and TLC with an authentic sample previously isolated from
our group confirmed the identity of compounds 3.
The 1H and 13C NMR spectra of compound 4 revealed a flavanone core structure. The
distinct hydroxy peak at δH 12.1 confirmed the substitution at C-5 and further confirmed the
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carbonyl to be at C-4. The singlet at δH 6.05 (H-6) was consistent with a hydrogen surrounded by
two hydroxy groups. The HMBC correlations confirmed ring-A to be penta-substituted.
Coupling patterns in the aromatic range of δH 7.39 – 7.59 were consistent with a monosubstituted ring-B. Coupling constants and HMBC correlations were consistent with a 3,3
dimethylallyl attached to C-8 (δC 108).
The 1H and 13C NMR spectra of compound 5 revealed an isoflavonoid core structure.
Proton and carbon correlations from HSQC revealed C-2 (δC 70.7) and C-4 (δC 31.7) to be
methylene carbons. The DEPT and HSQC of δC 32.6 (C-3) revealed a methane, and HMBC of
its respective hydrogen (H-3, δH 3.47) revealed two neighboring methylene carbons and the
attachment carbon to ring-C. Aromatic coupling constants confirmed ring A to be tetrasubstituted. Coupling constants and HMBC correlations were consistent with a 3,3-dimethylallyl
located at C-8 (δC 116). Coupling constants and HMBC correlations revealed ring-C to be
trisubstituted. The 3JCH between δH 3.47 (H-3) and an oxygenated carbon revealed C-2¢ to be δC
157. Coupling constants and HMBC correlations confirmed the methoxy to be attached at C-4¢
(δC 160).
The 1H and 13C NMR spectra of compound 6 revealed a flavanone core structure. The
distinct hydroxy group at C-5 (δC 163, δH 12.2) intermolecularly hydrogen bonded to the
carbonyl at C-4 (δC 198) was seen. The chemical shift and HMBC correlations of H-6 (δH 6.01)
revealed ortho hydroxy groups and penta-substitution for ring-A. The 3,3-dimethylallyl was
determined to be attached to ring-A because of the 2JCH correlation between H-1¢¢ (δH 3.23) and
C-8 (δC 108). The combination of coupling constants, chemical shifts, and HMBC correlations
revealed the unsubstituted carbons on ring-C to be C-3¢ and C-6¢. The 1,1-dimethylallyl was
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determined to be attached to ring-C because of the 3JCH correlation between H-1¢¢¢ (δH 1.47) and
C-5¢ (δC 126.2).
Compound 1: (+)-medicarpin;23 yellow oil; [α]D: +168 (c 0.125 mg/mL, MeOH);23 UV (MeOH)
lmax (log e) 206 (4.71), 228 (sh) (4.16), 281 (sh) (3.95), 287 (3.99); IR (film on KBr) nmax 3350
(br OH), 1621, 1507, 1278, 1154, 1114, 1083, 1028, 950 cm-1; 1H and 13C NMR spectroscopic
data (acetone-d6, 400 MHz, Figures S1 and S2) and TLC comparison revealed 1 to be identical
to an authentic sample.23
Compound 2: (+)-4-hydroxymedicarpin;37 [α]D: +86.5 (c 0.2 mg/mL, MeOH);37 UV (MeOH)
lmax (log e) 208 (4.61), 236 (sh) (3.86), 285 (3.58); IR (film on KBr) nmax 3394 (br OH), 1623,
1576, 1558 cm-1; 1H and 13C NMR spectroscopic data (acetone-d6, 400 MHz, Figures S5 and S6)
and TLC comparison revealed 2 to be identical to an authentic sample.
Compound 3: (-)-euchrenone-a7;23 orange oil; [α]D: -37.0 (c 0.2 mg/mL, MeOH);23 UV (MeOH)
lmax (log e) 203 (4.58), 221 (sh) (4.37), 235 (sh) (4.17), 285 (4.11); IR (film on KBr) nmax 3366
(br OH), 1600, 1558, 1541, 1438, 1287 cm-1; 1H and 13C data (acetone-d6, 400 MHz, Figures S7
and S8) were consistent with published values.23
Compound 4: (-)-glabranine;38,39 [α]D: -72.0 (c 0.2 mg/mL, MeOH);38,39 UV (MeOH) lmax (log e)
203 (4.62), 208 (sh) (4.54), 216 (sh) (4.45), 246 (sh) (3.94), 294 (4.26), 334 (3.61); IR (film on
KBr) nmax 3386 (br OH), 1636, 1603, 1559, 1507, 1456, 1437 cm-1; 1H NMR data (acetone-d6,
400 MHz, Figures S9 - 12) d 12.1 (OH, s, H-5), 7.6 (2H, d, J = 7.4 Hz, H-2¢, 6¢), 7.5 (2H, t, J =
7.4 Hz, H-3¢, 5¢), 7.4 (1H, t, J = 7.2, H-4¢), 6.1 (1H, s, H-6), 5.6 (1H, dd, J = 3.0, 12.6 Hz, H-2),
5.2 (1H, t, J = 7.0 Hz, H-2¢¢), 3.3 (2H, d, J = 6.7 Hz, H-1¢¢), 3.1 (1H, dd, J = 12.6, 17.1 Hz, H3a), 2.8 (1H, dd, J = 3.0, 17.1 Hz, H-3b), 1.6 (3H, s, H-Me-3¢¢), 1.6 (3H, s, H-4¢¢); 13C NMR
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data (acetone-d6, 400 MHz) d 197.3 (C, C-4), 165.1 (C, C-7), 163.1 (C, C-5), 160.9 (C, C-9),
140.4 (C, C-1¢), 131.4 (C, C-3¢¢), 129.5 (CH, C-3¢, 5¢), 129.4 (CH, C-4¢), 127.2 (CH, C-2¢, 6¢),
123.7 (CH, C-2¢¢), 108.4 (C, C-8), 103.4 (C, C-10), 96.6 (CH, C-6), 79.8 (CH, C-2), 43.6 (CH2,
C-3), 26.0 (CH3, C-4¢¢), 22.4 (CH2, C-1¢¢), 18.0 (CH3, C-Me-3¢¢); HMBC correlations (acetoned6) H-2 à C-1¢, 2¢; H-3α à C-2, 4, 1¢; H-3β à C-4; OH-5 à C-4, 5, 6, 7, 10; H-6 à C-5, 7, 8,
9, 10, 1¢¢; H-7 à C-6, 7, 8, 9; H-2¢/6¢ à C-2, 2¢/6¢, 4¢; H-3¢/5¢ à C-1¢, 3¢/5¢; H-4¢ à C-2¢/5¢; H1¢¢ à C-8, 10, 2¢¢, Me-3¢¢, 4¢¢; H-2¢¢ à C-7, 9, 3¢¢; H-Me-3¢¢ à C-2¢¢, 3¢¢; H-4¢¢ à C-2¢¢, 3¢¢.
Compound 5: (-)-4¢-O-methylpreglabridin;40 Pale yellow oil; [α]D: -8.0 (c 0.2 mg/mL, MeOH);
UV (MeOH) lmax (log e) 206 (4.67), 229 (sh) (4.17), 281 (3.65) 286 (3.64); IR (film on KBr)

nmax 3417 (br OH), 1616, 1595, 1519, 1455, 1431, 1081 cm-1; 1H NMR data (400 MHz, acetoned6, Figures S13 – S16) d 7.1 (1H, d, J = 8.4 Hz, H-6¢), 6.7 (1H, d, J = 8.2 Hz, H-5), 6.5 (1H, d, J
= 2.5 Hz, H-5¢), 6.4 (1H, dd, J = 2.5 Hz, H-3¢), 6.39 (1H, d, J = 8.2 Hz, H-6), 5.3 (1H, t, H-2¢¢),
4.3 (2H, dd, J = 2.1, 10.2 Hz, H-2a), 4.0 (2H, t, H-2b), 3.7 (3H, s, OCH3), 3.5 (1H, m, H-3), 3.3
(2H, d, J = 6.8 Hz, H-1¢¢), 3.0 (2H, dd, J = 11.0, 15.4 Hz, H-4a), 2.8 (2H, dd, J = 3.0, 15.5 Hz,
H-4b), 1.7 (3H, 1, CH3), 1.6 (3H, s, CH3); 13C NMR data (acetone-d6, 400 MHz) d 160.4 (C, C4¢), 156.8 (C, C-2¢), 154.8 (C, C-7), 153.8 (C, C-9), 130.7 (C, C-3¢¢), 128.9 (CH, C-6¢), 127.8
(CH, C-5), 124.5 (CH, C-2¢¢), 121.2 (C, C-1¢), 116.1 (C, C-8), 114.4 (C, C-10), 108.4 (CH, C-6),
105.8 (CH, C-5¢), 102.6 (CH, C-3¢), 70.7 (CH2, C-2), 55.4 (CH3, OCH3), 32.6 (CH, C-3), 31.7
(CH2, C-4), 26.0 (CH3, C-4¢¢a), 23.1 (CH2, C-1¢¢), 18.0 (CH3, C-3¢¢-Me); HMBC correlations
(acetone-d6) H-2a à C-4, 9, 1¢; H-2b à C-4, 9, 1¢; H-3 à C-4,1¢, 2¢, 6¢; H-5 à C-4, 6, 7, 8, 9;
OH-7 à C-6, 7, 8; OH-2¢ à C-,1¢, 2¢, 3; H-3¢ à C-3, 1¢, 2¢, 4¢, 5¢; OCH3-4¢ à C-4¢; H-5¢ à C1¢, 3¢, 4¢; H-6¢ à C-3, 2¢, 3¢, 4¢; H-1¢¢ à C-7, 8, 9, 2¢¢, 3¢¢, 4¢¢; H-2¢¢ à C-8, 1¢¢, 4¢¢, 3¢¢-Me.
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Compound 6: 2(S)-5¢-(1¢¢¢,1¢¢¢-dimethylallyl)-8-(3¢¢,3¢¢-dimethylallyl)-2¢,4¢,5,7tetrahydroxyflavanone;41 [α]D: -21.5 (c 0.2 mg/mL, MeOH); UV (MeOH) lmax (log e) 203
(4.72), 229 (sh) (4.31), 291 (4.22); IR (film on KBr) nmax 3408 (br OH), 1635, 1604, 1505, 1430,
1380, 1301, 1171, 1076 cm-1; 1H NMR data (400 MHz, acetone-d6, Figures S17 – S20) δ 12.2
(OH, s, H-5), 7.4 (1H, s, H-6¢), 6.5 (1H, s, H-3¢), 6.3 (1H, dd, J = 10.7, 17.6 Hz, H-3¢¢¢), 6.0 (1H,
s, H-6), 5.7 (1H, dd, J = 2.9, 12.9, H-2), 5.3 (1H, t, H-2¢¢), 5.0 (2H, dd, J = 14.1, 16.7 Hz, H-4¢¢¢),
3.2 (2H, dd, 7.2, 18.1 Hz, H-1¢¢), 3.1 (2H, dd, J = 12.9, 17.1 Hz, H-3α), 2.8 (2H, dd, J = 3.0, 17.1
Hz, H-3β), 1.6 (3H, s, H-3¢¢), 1.6 (3H, s, H-4¢¢), 1.5 (3H, s, H-1¢¢¢), 1.5 (3H, s, H-Me-2¢¢¢); 13C
NMR data (acetone-d6, 400 MHz) d 198 (C, C-4), 165 (C, C-7), 163 (C, C-5), 161 (C, C-9), 157
(C, C-4¢), 154 (C, C-2¢), 149 (CH, C-3¢¢¢), 131 (C, C-3¢¢), 126.4 (CH, C-6¢), 126.2 (C, C-5¢), 124
(CH, C-2¢¢), 117 (C, C-1¢), 110 (CH2, C-4¢¢¢), 108 (C, C-8), 105 (CH, C-3¢), 103 (C, C-10), 96.2
(CH, C-6), 75.6 (CH, C-2), 42.7 (CH2, C-3), 40.7 (C, C-2¢¢¢), 27.5 (CH3, C-1¢¢¢), 27.5 (CH3, CMe-2¢¢¢), 25.9 (CH3, C-Me-3¢¢), 22.2 (CH2, C-1¢¢), 17.9 (CH3, C-4¢¢); HMBC correlations
(acetone-d6) H-3 à 4, 1¢, 2¢, 6¢; H-3a à C-2, 4, 1¢; H-3b à C-4; OH-5 à 4, 5, 6, 7, 10; H-6 à
C-4, 5, 7, 8, 10, 1¢¢; H-3¢ à C-2, 1¢, 2¢, 4¢, 5¢, 2¢¢¢; H-6¢ à C-2, 1¢, 2¢, 3¢, 4¢, 5¢, 2¢¢¢, 3¢¢¢; H-1¢¢ à
C-7, 8, 9, 2¢¢, 3¢¢; H-2¢¢ à C-8, 1¢¢, Me-3¢¢, 4¢¢; H-Me-3¢¢ à C-3¢¢; H-4¢¢ à C-3¢¢; H-1¢¢¢ à C-5¢,
2¢¢¢, 3¢¢¢, 4¢¢¢; H-Me-2¢¢¢ à C-5¢, 2¢¢¢, 3¢¢¢, 4¢¢¢; H-3¢¢¢ à C-5¢, 6¢, 1¢¢¢, 2¢¢¢, Me-2¢¢¢; H-4¢¢¢ à C-1¢¢¢,
2¢¢¢, Me-2¢¢¢, 3¢¢¢.
Dalea albiflora - Experimental
Optical rotations were recorded on a PerkinElmer 341 polarimeter (Na lamp, 589 nm);
concentrations are reported as g/ 100 mL. UV spectra were recorded using an HP-Agilent 8453
photodiode array instrument. IR spectra were obtained on a Nicolet Protégé 460 spectrometer,
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via KBr plates. NMR spectra were obtained on a Bruker Avance 400 MHz system with Topsin
1.3 software. TLC plates (Sigma-Aldrich; silica gel 60, F254) were eluted with mixtures of MeOH
in DCM or of EtOAc in hexanes. Spots were visualized with UV (254 nm) and scorched after
being sprayed with reagent vanillin – H2SO4 (1 g/ 100 mL w/v). All solvents were purchased
from Sigma-Aldrich.
The crude extract of aerial portions of D. albiflora was fractionated into eleven VLC
fractions. VLC fractions four, five and six were combined in a 2.08 g representative (by weight)
mixture and passed through a Sephadex LH-20 column. The known compound (+)-medicarpin
(1),23 8.1 mg, was then isolated after a step gradient and linear gradient column. The known
compound (+)-maackiain (7),23 10.8 mg, was isolated after one additional step gradient column.
The crude extract of the roots of D. albiflora led to eleven VLC fractions. Since VLC
fraction two was only 168.6 mg, this entire fraction was chromatographed over Sephadex LH-20,
eluting for 24 hrs. Sephadex fractions were collected in 8 mL portions. The components of VLC
fraction two materials were collected in Sephadex test tube fractions 1 – 55. VLC fractions three
and four were then combined (2.26 g) and loaded (at 24 h) onto the same column, which was by
then largely cleared of any remaining substances. Fraction three was 1080.5 mg; the entire
sample was used, and 1179.5 mg of fraction four was added to make the mixture. The
combination of VLC fractions three and four were added to the column while Sephadex fraction
45 was being collected. The remaining eluent was collected as Sephadex fractions 56 – 215.
Fractions 1- 55 were combined into vials 1 – 9, and fractions 56 – 215 were combined into vials
10 – 77. The known compound 2(S)-5¢-(1¢¢¢,1¢¢¢-dimethylallyl)-8-(3¢¢,3¢¢-dimethylallyl)-2¢,4¢,5,7tetrahydroxyflavanone (6), 15.3 mg, was then isolated after three linear gradient columns. The
known compound 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)-2’-methoxy-4’,5,7-
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trihydroxyflavanone (8), 4.7 mg, was isolated after one linear gradient column. The new
compound albifloran A (9), 7.0 mg, was isolated after one linear gradient column and one linear
isocratic column. The new compound albifloran B (10), 3.5 mg, was isolated after one linear
gradient column.
Dalea albiflora - Results and Discussion
The components of the initial crude extract of D. albiflora were exposed to S. cerevisiae
(over expressing the Pdr5, Snq2 and Yor1 efflux pumps), C. albicans (over expressing the Cdr1
and Yor1efflux pumps), and C. glabrata (over expressing the Cdr1and Yor1 efflux pumps). The
efflux pumps in Pdr5 S. cerevisiae, Cdr1 C. albicans and glabrata all inactivated the components
of the crude root extracts. The Snq2 S. cerevisiae transporter weakly inactivated the components
of the crude root extracts. The Yor1 S. cerevisiae, C. albicans and glabrata had no effect on the
components of the crude root extracts with a MIC of 167 µg/mL.
The components of VLC fractions two, three, four and six were exposed to an S.
cerevisiae expression host (hypersensitive strain without efflux pump genes), Pdr5 and Snq2 S.
cerevisiae, Cdr1 C. albicans, and Snq2 C. glabrata. The components of VLC fractions three and
four exhibited growth inhibition of the expression host with a MIC of 42 µg/mL. The
components of VLC fractions three and four inhibited the growth of Snq2 S. cerevisiae with a
MIC of 87 µg/mL. The components of VLC fraction four inhibited the growth of Snq2 C.
glabrata with a MIC of 167 µg/mL. The components of VLC fractions two, three, four and six
were all ineffective in inhibiting the growth of Pdr5 S. cerevisiae and Cdr1 C. albicans. The
growth inhibition of the Snq2 overexpressing S. cerevisiae and C. glabrata suggests that
something inside VLC fractions three and four is deactivating the Snq2 transporter. With higher
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purification of the fractions, it is anticipated that the MIC would decrease. Prior work, from our
research group, has shown that less pure samples antagonize the effects of active molecules.
Protons and carbons were correlated using HSQC. Complete connectivity was
determined be HMBC. Compounds 1 and 7 were isolated from the aerial portions of D. albiflora.
Compounds 1, 6, 8, 9, and 10 were isolated from the root portions of D. albiflora. The structures
of these compounds are shown in Figure 13.

Figure 13: The structures of isolated metabolites of D. albiflora.
The 1H and 13C NMR spectra of compounds 1 and 7 revealed a pterocarpan core
structure. Comparison of spectroscopy data and TLC with authentic samples previously isolated
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from the Belofsky group confirmed the identities compounds 1 and 7 to be (+)-medicarpin and
(+)-maackiain.
The 1H and 13C NMR spectra of compound 6 revealed a flavanone core structure.
Comparison of spectroscopy data and TLC with authentic samples previously isolated in the
Belofsky lab confirmed the identity of compound 6. Infrared spectroscopic data further
confirmed the identity of compound 6 to be isolated in root portions of both D. mollis and D,
albiflora.
The 1H and 13C NMR spectra of compound 8 revealed a flavanone core structure. The 1H
and 13C NMR confirmed the distinct hydroxy at C-5 (dC 163) hydrogen bonded to the carbonyl at
C-4(dC 198). The presence of a penta-substituted ring was confirmed by HMBC correlation of H6 (dH 6.0). The 3,3-dimethylallyl attachment point was confirmed by the 2JCH correlation
between H-1¢¢ (dH 3.2) and C-8 (109). The 1,1-dimethylallyl attachment point was confirmed by
the 3JCH correlation between H-1¢¢¢ (dH 1.5) and C-5¢ (127). The methoxy hydrogens at dH 3.8
correlated to an oxygenated aromatic carbon at dC 157. This carbon was confirmed to be C-2¢
from a 3JCH correlation between H-2 (dH 5.7) and C-2¢ (157). The chemical shift and HMBC
correlations confirmed the substitution pattern for ring-C.
The 13C NMR (100 MHz, Table 1), and DEPT data for compound 9 indicated a
molecular formula of C25H28O6. The flavanone core structure was identified by HSQC
correlations between the oxymethine at dH 5.7 (dd, H-2) coupled to the methylene protons at dH
3.2 (dd, H-3a) and 2.7 (dd, H-3b) and their respective carbons at dC 76.7 and 42.6. The 13C NMR
and DEPT data indicated thirteen protonated carbons, as well as a keto carbonyl at dC 198 and
five oxygenated sp2 carbons between dC 154 and 165. Only one of the hydroxy groups had an
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identifiable proton at dH 12.2, which is consistent with a hydroxy group at C-5 being hydrogenbonded to a carbonyl at C-4.23
Table 1: NMR Spectroscopic Data (Acetone-d6) for Albifloran A (9).
position dC, type
HMBCa
dH (J in Hz)
2
76.7, CH
5.7, dd (13.0, 2.64)
4, 1¢, 2¢, 6¢
3α
42.6, CH2 3.2, dd (3.96)
2, 4, 1¢
3β
2.7, dd (17.1, 2.80)
2, 10
4
198.1, C
5
163.1, C
OH-5
12.2, s
4b, 5, 6, 7, 10
6
96.3, CH
6.0, s
4b, 5, 7, 8, 10, 1¢¢b
7
164.9, C
OH-7
not observed
not observed
8
108.5, C
9
161.4, C
10
103, C
118.3, C
1¢
154.2, C
2¢
not observed
not observed
OH-2¢
116.6, C
3¢
157.1, C
4¢
not observed
not observed
OH-4¢
108.2, CH 6.5, d (8.40)
5¢
1¢, 2¢, 3¢, 4¢, 1¢¢¢b
125.6, CH 7.2, d (8.40)
6¢
2, 2¢, 3¢, 4¢
22.4,
CH
3.2,
d
(7.16)
1¢¢
7, 8, 9, 2¢¢, 3¢¢, 3¢¢-Me, 4¢¢
2
123.7, CH 5.2, t (7.16)
2¢¢
8, 1¢¢, 3¢¢-Me, 4¢¢
131.4, C
3¢¢
25.9, CH3 1.7, s
Me-3¢¢
17.9, CH3 1.6, s
4¢¢
2¢¢, 3¢¢, 3¢¢-Me
23.1, CH2 3.4, d (6.80)
1¢¢¢
2¢, 3¢, 4¢, 2¢¢¢, 3¢¢¢, 3¢¢¢-Me, 4¢¢¢
123.8, CH 5.3, t (6.96)
2¢¢¢
3¢, 1¢¢¢, 3¢¢¢-Me, 4¢¢¢
131.9, C
3¢¢¢
18.1, CH3 1.8, s
Me-3¢¢¢
2¢¢¢, 3¢¢¢, 4¢¢¢
25.9, CH3 1.6, s
4¢¢¢
a
HMBC correlations, optimized for 8.9 Hz, are from proton(s) stated to the
indicated carbon. bIndicates weak 4-bond correlation.
The prenyl group attached to ring-A was determined through a 2JCH correlation between H-1¢¢
(dH 3.2) and C-8 (dC 108). The prenyl group attached to ring-B was determined through a 2JCH
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correlation between H-1¢¢¢ (dH 3.4) and C-3¢ (dC 116). The substitution pattern for ring-A was
determined by the presence of a hydrogen singlet at dH 6.0 (H-6) with its respective carbon at dC
96.3. This strong relative shielding effect is consistent with a carbon ortho to two hydroxy
groups.17,22,23 The substitution pattern for ring-B was determined through a 3JCH correlation
between H-2 (dH 3.2) and an oxygenated carbon (C-2¢, dC 154). The additional 3JCH correlation
between H-2 (dH 3.2) and C-6¢ (dC 125). The hydrogen on C-6¢ is coupled to an adjacent
hydrogen (H-5¢, dH 6.5). A weak four-bond correlation between H-5¢ (dH 6.5) and C-1¢¢¢ (dC 23.1)
confirms that the prenyl group is meta to the ring attachment point. The most similar structures
have been identified as euchrestaflavanone B and cudraflavanone D.42,43 The key differences
between these structures are the prenyl groups on this new flavanone are located at C-8 and C-3¢.
In euchrestaflavanone B, the prenyl groups are located on C-8 and C-5¢.42 In cudraflavanone D,
the prenyl groups are located on C-6 and C-5¢.43 Coupling between H-5¢ and H-6¢ (J = 8.4 Hz)
was vital in the determination of the structure. Since this new flavanone structure is distinctly
different from both similar structures, and isolated from a different species, compound 9 has
been named albifloran A.
The 13C NMR (100 MHz, Table 2) and DEPT data for compound 10 indicated a
molecular formula of C25H28O6. The flavanone core structure was identified by HSQC
correlations between the oxymethine at dH 5.7 (dd, H-2) coupled to the methylene protons at dH
3.2 (dd, H-3a) and 2.8 (dd, H-3b) and their respective carbons at dC 71.3 and 37.6. The 13C NMR
and DEPT data indicated thirteen protonated carbons, as well as a keto carbonyl at dC 193 and
five oxygenated sp2 carbons between dC 149 and 158. Only one of the hydroxy groups had an
identifiable proton at dH 11.9, which is consistent with a hydroxy group at C-5 being hydrogen-
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bonded to the carbonyl at C-4.23 Due to the low mass of the sample, some anticipated HMBC
correlations did not appear. The singlet H-3¢ (dH 6.5) was determined to be meta to the ring
attachment (C-1¢) by a weak 4JCH correlation between H-3¢ (dH 6.5) and C-2 (dC 71.3).
Table 2: NMR Spectroscopic Data (Acetone-d6) for Albifloran B (10).
position dC, type
HMBCa
dH (J in Hz)
2
71.3, CH
5.7, d (12.8, 2.88)
1¢, 6¢
3α
37.6, CH2
2.8, dd (14.1, 2.88)
4
3β
3.2, dd (13.1, 4.08)
2, 4, 1¢
4
193.2, C
5
157.7,C
OH-5
11.9, s
5, 6, 10
6
92.6, CH
5.8, s
5, 7, 8, 10
7
158.7, C
8
96.7, C
9
156.8, C
10
98.5, C
111.9, C
1¢
152.5, C
2¢
not observed
not observed
OH-2¢
100.0, CH
6.5, s
3¢
2b, 1¢, 2¢, 4¢, 5¢
149.7, C
4¢
not observed
not observed
OH-4¢
121.5,
C
5¢
121.9, CH
7.4, s
6¢
2, 2¢, 4¢, 2¢¢¢
12.2, CH2
2.6, m (6.92)
1¢¢
7, 8, 9, 2¢¢, 3¢¢
27.7, CH2
1.8, m (6.76, 7.04)
2¢¢
8, 1¢¢, 3¢¢
72.0, C
3¢¢
21.9, CH3
1.3, s
Me-3¢¢
22.5, CH3
1.3, s
4¢¢
22.7, CH3
1.5, s
1¢¢¢
36.1, C
2¢¢¢
27.7, CH3
1.5, s
Me-2¢¢¢
144.3, CH
6.3, dd (10.6, 17.0)
3¢¢¢
1¢¢¢, 2¢¢¢, Me-2¢¢¢
105.7, CH2
4.9, d (10.7)
4¢¢¢
3¢¢¢
5.0, d (17.5)
2¢¢¢, 3¢¢¢
a
HMBC correlations, optimized for 8.9 Hz, are from proton(s) stated to the
indicated carbon. bIndicates weak 4-bond correlation.
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Due to the large up-field chemical shift and the 2JCH of two oxygenated carbons, ring-B was
determined to have hydroxy groups at C-2¢(dC 152) and C-4¢ (dC 150). The 3JCH correlation
between H-6¢ (dH 7.4) and C-2 (dC 71.3) suggests that H-6¢ must be ortho to the attachment
position (C-1¢). This leaves the attachment point of the vinylic prenyl group at C-5¢. This
attachment is further supported by the 3JCH correlation between H-6¢ (dH 7.4) and C-2¢¢¢ (dC 36.1).
A structure similarity search revealed the most similar structure to be kenusanone J.44
Kenusanone J lacks the 1,1-dimethylallyl group at C-5¢. In the reference paper, the authors
mention how the chemical shift of OH-5 (dH 11.9) is more downfield than expected. Since this
new flavanone structure is distinctly different from any published structure, compound 10 has
been named albifloran B.
Compound 1: (+)-medicarpin; yellow oil, [α]D: +111.5 (c 0.2 mg/mL, MeOH); UV (MeOH) lmax
(log e) 206 (4.68), 229 (sh) (4.05), 281 (sh) (3.80), 287 (3.85); IR (film on KBr) nmax 3401 (br
OH), 1622, 1599, 1497, 1472, 1346, 1278, 1157, 1115, 1084, 1030, 949 cm-1; 1H and 13C NMR
spectroscopic data (acetone-d6, 400 MHz); Figure S3 and Figure S4, and TLC comparison
revealed 1 to be identical to an authentic sample.23
Compound 6: 2(S)-5¢-(1¢¢¢,1¢¢¢-dimethylallyl)-8-(3¢¢,3¢¢-dimethylallyl)-2¢,4¢,5,7tetrahydroxyflavanone;41 [α]D: -79.5 (c 0.2 mg/mL, MeOH);41 UV (MeOH) lmax (log e) 204
(4.76), 228 (sh) (4.35), 291 (4.25); IR (film on KBr) nmax 3433 (br OH), 2967, 2916, 1636, 1605,
1504, 1430, 1381, 1300, 1170, 1076 cm-1; 1H and 13C NMR data (acetone-d6, 400 MHz) were
consistent with an authentic and published values (1H and 13C spectroscopic data Figures S21 –
S22).
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Compound 7: (+)-maackiain; pale yellow oil; [α]D: +184.5 (c 0.2 mg/mL, MeOH);23,45,46 UV
(MeOH) lmax (log e) 205 (4.65), 232 (sh) (3.93), 280 (sh) (3.60), 287 (3.66), 310 (3.84); IR (film
on KBr) nmax 3420 (br OH), 1618, 1596, 1507, 1474, 1457, 1147, 1120, 1034 cm-1; 1H and 13C
NMR data (acetone-d6, 400 MHz) were consistent with published values45 (1H and 13C
spectroscopic data Figures S23 – S24).
Compound 8: 2(S)-5¢-(1¢¢¢,1¢¢¢-dimethylallyl)-8-(3¢¢,3¢¢-dimethylallyl)-2¢-methoxy-4¢,5,7trihydroxyflavanone;41 [α]D: -91.0 (c 0.2, MeOH);41 UV (MeOH) lmax (log e) 204 (4.84), 216
(sh) (4.51), 230 (sh) (4.35), 291 (4.25), 342 (sh) (3.67); ( IR (film on KBr) nmax 3397 (br OH),
2976, 2917, 1596, 1452, 1416, 1308, 1121, 1081 cm-1; 1H NMR data (acetone-d6, 400 MHz,
Figures S25 – S28) d 12.2 (OH, s, H-5), 9.6 (OH, s, H-7), 8.2 (OH, s, H-4¢), 7.5 (1H, s, H-6¢),
6.6 (1H, s, H-3¢), 6.3 (1H, dd, J = 6.5, 10.7 Hz, H-3¢¢¢), 6.0 (1H, s, H-6), 5.7 (1H, dd, J = 2.9,
10.0 Hz, H-2), 5.2 (1H, t, H-2¢¢), 5.0 (2H, dd, J = 1.2, 17.6 Hz, H-4¢¢¢α), 5.0 (2H, dd, 1.3, 10.7
Hz, H-4¢¢¢β), 3.8 (3H, s, OCH3), 3.2 (2H, dd, J = 7.2, 21.9 Hz, H-1¢¢), 3.1 (1H, dd, J = 12.9, 17.1
Hz, H-3α), 2.7 (1H, dd, J = 3.0, 17.1 Hz, H-3β), 1.6 (3H, s, H-4¢¢), 1.6 (3H, s, H-Me-3¢¢), 1.5
(3H, s, H-1¢¢¢), 1.5 (3H, s, H-Me-2¢¢¢); 13C NMR data (acetone-d6, 400 MHz) δ 198 (C, C-4), 165
(C, C-7), 163 (C, C-5), 162 (C, C-9), 158 (C, C-4¢), 157 (C, C-2¢), 149 (CH, C-3¢¢¢), 132 (C, C3¢¢), 127 (CH, C-6¢), 127 (C, C-5¢), 124 (CH, C-2¢¢), 119 (C, C-1¢), 111 (CH2, C-4¢¢¢), 109 (C, C8), 104 (C, C-10), 101 (CH, C-3¢), 96.8 (CH, C-6), 75.8 (CH, C-2), 56.4 (CH3, OCH3), 43.4
(CH2, C-3), 41.3 (C, C-2¢¢¢), 28.0 (CH3, C-1¢¢¢), 27.9 (CH3, C-Me-2¢¢¢), 26.4 (CH3, C-Me-3¢¢),
22.8 (CH2, C-1¢¢), 18.4 (CH3, C-4¢¢); HMBC correlations (acetone-d6) H-2 à C-4, 1¢, 2¢, 6¢; H-3α
à C-2, 4, 1¢; H-3β à C-4; OH-5 à C-5, 6, 10; H-6 à C-4, 5, 8, 9, 10, 1¢¢; OH-7 à C-7, 8;
OCH3-2¢ à C-2¢; H-3¢ à C-2, 1¢, 2¢, 4¢, 5¢, 6¢, 1¢¢¢; H-4¢ à C-3¢, 4¢, 5¢; H-6¢ à C-2, 3, 1¢, 2¢, 3¢,
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4¢; H-1¢¢ à C-7, 8, 9, 2¢¢, 3¢¢; H-2¢¢ à C-1¢¢, Me-3¢¢, 4¢¢; H-Me-3¢¢ à C-2¢¢, 3¢¢, Me-3¢¢, 4¢¢; H-4¢¢
à C-2¢¢, 3¢¢, Me-3¢¢, 4¢¢; H-1¢¢¢ à C-5¢, 2¢¢¢, Me-2¢¢¢, 3¢¢¢; H-Me-2¢¢¢ à C-5¢, 1¢¢¢, 2¢¢¢, 3¢¢¢; H-3¢¢¢
à C-5¢, 1¢¢¢, 2¢¢¢, Me-2¢¢¢; H-4¢¢¢ à C-1¢¢¢, 2¢¢¢, Me-2¢¢¢, 3¢¢¢, H-4¢¢¢ à C-1¢¢¢, 2¢¢¢, Me-2¢¢¢, 3¢¢¢.
Compound 9: albifloran A; [α]D: -41.5 (c 0.2, MeOH); UV (MeOH) lmax (log e) 205 (5.03), 208
(sh) (4.99), 212 (sh) (4.89), 225 (sh) (4.64), 293 (4.39), 337 (sh) (3.75); IR (film on KBr) nmax
3401 (br OH), 2978, 2916, 1636, 1604, 1457, 1382, 1302, 1173, 1073 cm-1; 1H, 13C, and HMBC
NMR data refer to Table 1 and Figures S29 – S32.
Compound 10: albifloran B; [α]D: -58.5 (c 0.2, MeOH); UV (MeOH) lmax (log e) 202 (4.75), 232
(sh) (4.18), 292 (4.12); IR (film on KBr) nmax 3395 (br OH), 1646, 1636, 1590, 1558, 1541,
1507, 1457 cm-1; 1H, 13C, and HMBC NMR data refer to Table 2 and Figures S33 – S36.
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Appendix A - NMR Spectra
Figure S1: The proton NMR of (+)-medicarpin (1) of D. mollis.
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Figure S2: The carbon NMR of (+)-medicarpin (1) of D. mollis.
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Figure S3: The proton NMR of (+)-medicarpin (1) of D. albiflora.
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Figure S4: The proton NMR of (+)-medicarpin (1) of D. albiflora.
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Figure S5: The proton NMR of (+)-4-hydroxymedicarpin (2) of D. mollis.
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Figure S6: The carbon NMR of (+)-4-hydroxymedicarpin (2) of D. mollis.
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Figure S7: The proton NMR of (-)-euchronone-a7 (3) of D. mollis.
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Figure S8: The carbon NMR of (-)-euchronone-a7 (3) of D. mollis.
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Figure S9: The proton NMR of (-)-glabranine (4) of D. mollis.
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Figure S10: The carbon NMR of (-)-glabranine (4) of D. mollis.
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Figure S11: The HSQC NMR of (-)-glabranine (4) of D. mollis.
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Figure S12: The HMBC NMR of (-)-glabranine (4) of D. mollis.
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Figure S13: The proton NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S14: The carbon NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S15: The HSQC NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S16: The HMBC NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S17: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.
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Figure S18: The carbon NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.
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Figure S19: The HSQC NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.
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Figure S20: The HMBC NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.
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Figure S21: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. albiflora.
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Figure S22: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. albiflora.
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Figure S23: The proton NMR of (+)-maackiain (7) of D. mollis.
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Figure S24: The carbon NMR of (+)-maackiain (7) of D. mollis.
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Figure S25: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.
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Figure S26: The carbon NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.

73

Figure S27: The HSQC NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.
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Figure S28: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.
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Figure S29: The proton NMR of the new flavanone albifloran A (9) of D. albiflora.
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Figure S30: The carbon NMR of the new flavanone albifloran A (9) of D. albiflora.
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Figure S31: The HSQC NMR of the new flavanone albifloran A (9) of D. albiflora.
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Figure S32: The HMBC NMR of the new flavanone albifloran A (9) of D. albiflora.
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Figure S33: The proton NMR of the new flavanone albifloran B (10) of D. albiflora.
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Figure S34: The carbon NMR of the new flavanone albifloran B (10) of D. albiflora.
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Figure S35: The HSQC NMR of the new flavanone albifloran B (10) of D. albiflora.
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Figure S36: The HMBC NMR of the new flavanone albifloran B (10) of D. albiflora.
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47

Figure S1: The proton NMR of (+)-medicarpin (1) of D. mollis.
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Figure S2: The carbon NMR of (+)-medicarpin (1) of D. mollis.
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Figure S3: The proton NMR of (+)-medicarpin (1) of D. albiflora.
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Figure S4: The proton NMR of (+)-medicarpin (1) of D. albiflora.
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Figure S5: The proton NMR of (+)-4-hydroxymedicarpin (2) of D. mollis.
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Figure S6: The carbon NMR of (+)-4-hydroxymedicarpin (2) of D. mollis.
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Figure S7: The proton NMR of (-)-euchronone-a7 (3) of D. mollis.
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Figure S8: The carbon NMR of (-)-euchronone-a7 (3) of D. mollis.

55

Figure S9: The proton NMR of (-)-glabranine (4) of D. mollis.
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Figure S10: The carbon NMR of (-)-glabranine (4) of D. mollis.
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Figure S11: The HSQC NMR of (-)-glabranine (4) of D. mollis.
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Figure S12: The HMBC NMR of (-)-glabranine (4) of D. mollis.
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Figure S13: The proton NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S14: The carbon NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S15: The HSQC NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S16: The HMBC NMR of (-)-4¢-O-methylpreglabridin (5) of D. mollis.
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Figure S17: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.

64

Figure S18: The carbon NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.
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Figure S19: The HSQC NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.
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Figure S20: The HMBC NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. mollis.
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Figure S21: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. albiflora.
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Figure S22: The carbon NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)2’,4’,5,7-tetrahydroxyflavanone (6) of D. albiflora.
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Figure S23: The proton NMR of (+)-maackiain (7) of D. albiflora.
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Figure S24: The carbon NMR of (+)-maackiain (7) of D. albiflora.
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Figure S25: The proton NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.
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Figure S26: The carbon NMR of 2(S)-5’-(1’’’,1’’’-di-methylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.
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Figure S27: The HSQC NMR of 2(S)-5’-(1’’’,1’’’-dimethylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.
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Figure S28: The HMBC NMR of 2(S)-5’-(1’’’,1’’’-di-methylallyl)-8-(3’’,3’’-dimethylallyl)-2’methoxy-4’,5,7-trihydroxyflavanone (8) of D. albiflora.
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Figure S29: The proton NMR of the new flavanone albifloran A (9) of D. albiflora.

76

Figure S30: The carbon NMR of the new flavanone albifloran A (9) of D. albiflora.
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Figure S31: The HSQC NMR of the new flavanone albifloran A (9) of D. albiflora.
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Figure S32: The HMBC NMR of the new flavanone albifloran A (9) of D. albiflora.
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Figure S33: The proton NMR of the new flavanone albifloran B (10) of D. albiflora.
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Figure S34: The carbon NMR of the new flavanone albifloran B (10) of D. albiflora.
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Figure S35: The HSQC NMR of the new flavanone albifloran B (10) of D. albiflora.
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Figure S36: The HMBC NMR of the new flavanone albifloran B (10) of D. albiflora.
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